Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
Eli Lilly and Company
Eli Lilly and Company
M.D. Anderson Cancer Center
Memorial Sloan Kettering Cancer Center
Eastern Cooperative Oncology Group
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
National Institutes of Health Clinical Center (CC)
Novartis
Celldex Therapeutics
Rutgers, The State University of New Jersey
Eastern Cooperative Oncology Group
INSYS Therapeutics Inc
Dartmouth-Hitchcock Medical Center
National Cancer Institute (NCI)
Infinity Pharmaceuticals, Inc.
M.D. Anderson Cancer Center
Case Comprehensive Cancer Center